Lisinopril-Induced Angioedema in a Patient with Plasma Prekallikrein Deficiency

Swapan K. Dasgupta1  Stefanie Rivera1  Perumal Thiagarajan1,2,3

1 Department of Pathology, Baylor College of Medicine, Houston, Texas, United States
2 Department of Medicine, Baylor College of Medicine, Houston, Texas, United States
3 Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States

TH Open 2020;4:e33–e35.

Address for correspondence Perumal Thiagarajan, MD, Michael E. DeBakey VA Medical Center, Mail stop # 113, Houston, TX 77030, United States (e-mail: perumalt@bcm.edu).

A 67-year-old veteran came to our emergency department because of the sudden onset of tongue swelling and the inability to swallow saliva. His past medical history included type 2 diabetes mellitus, essential hypertension, and plasma prekallikrein deficiency. He had no itching or previous history of allergic reaction. He had been previously diagnosed to have plasma prekallikrein deficiency as his PTT had ranged from 90 to <120 seconds on different occasions (normal <35 seconds). The plasma kallikrein level was less 3% by coagulation assays. No immunoreactive prekallikrein was detected in the plasma by western blot (►Fig. 1). All other coagulation factors had been in the normal range, including factor XII. He had never had a bleeding diathesis. He started taking lisinopril for hypertension 3 months before the onset of angioedema. His physical examination was unremarkable except for oropharyngeal angioedema. He received intravenous dexamethasone, ranitidine, and diphenhydramine, and his symptoms resolved over several hours.

Deoxyribonucleic acid (DNA) was extracted from peripheral blood leukocytes and all 15 exons of prekallikrein gene (KLKB1) were amplified by polymerase chain reaction (PCR) using genomic DNA as the template and sequenced. He had a homozygous single nucleotide insertion of thymine in codon 132, in exon 5, that caused amino acid change (Ser to Phe) and frameshift of subsequent codons resulting in a premature stop at codon 173 (►Fig. 1). To our knowledge, this mutation has never been described before. This exon codes for the apple 2 domain and a previously described amino acid substitutions (Asn to Ser in codon 124) were also present.

Angiotensin-converting enzyme (ACE) not only catalyzes the conversion of angiotensin I to II but also degrades plasma bradykinin (which induces vasodilation and increased vascular permeability) by proteolysis to inactive metabolites2,3. Substantial increase in bradykinin levels during acute attacks has been shown in patients with ACE-induced angioedema.4 Occurrence of angioedema in a patient with complete deficiency of plasma prekallikrein due to homozygous mutation (Ser97PhefsTer173).
prekallikrein shows other possible enzymes capable of liberating bradykinin such as factor XIIa, plasmin, or tissue kallikreins may also play a role in generating bradykinin during ACE inhibitor therapy (► Fig. 2). Mutation of the angiopoietin-1 gene (ANGPT1) can also induce angioedema independent of bradykinin. These enzyme or proteins can be possible etiologies for angioedema independent of plasma kallikrein. In humans, plasma prekallikrein is coded by a single gene KLKB1, while tissue kallikreins are a family of 15 closely related serine proteases (KLK1-15). At least two tissue kallikreins, KLK1 and KLK2, can generate bradykinin from low molecular weight kininogen. Salivary secretion is a rich source of tissue kallikreins. The oropharynx with abundant saliva is the most common site of angioedema associated with ACE. It is pertinent to note that bradykinin, generated in the plasma during plasmapheresis or during infections, is associated with hypotension but not angioedema. These clinical observations raise the possibility that bradykinin generated by tissue kallikrein present in the salivary secretions may have a causal role in oropharyngeal angioedema in patients receiving ACE inhibitors.

Authors’ Contribution
P.T. analyzed and interpreted the data and wrote the manuscript. S.K.D. and S.R. performed the sequencing.

Funding
This study was supported in part by a grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (to P.T.), a grant from National Institutes of Health (HL139501 to P.T.). The contents of this manuscript are solely the responsibility of

Fig. 1. Mutation in prekallikrein gene. (A) Immunoblot of plasma. Two microliter of control and patient was electrophoresed and blotted with an antibody to plasma prekallikrein (clone 13G11 from Invitrogen). (B) Sequencing traces of PCR amplified exon 5 depicting the homozygous single nucleotide (') insertion in codon 132, leading to frameshift all of subsequent codons. PCR, polymerase chain reaction.

Fig. 2. The kallikrein proteolytic cascade. The preferred substrate for plasma kallikrein is high molecular weight kininogen while tissue kallikreins metabolize low and high molecular weight kininogen.
the authors and do not necessarily represent the views of the Department of Veterans Affairs or the United States Government.

Conflict of Interest
None declared.

References